Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis in androgen-independent human prostate cancer cell lines.
Kim I, Kim B, Seong D, Lee D, Seo J, Hong Y, Kim H, Morton R, Kim S. Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis in androgen-independent human prostate cancer cell lines. Cancer Research 2002, 62: 5365-9. PMID: 12235008.Peer-Reviewed Original ResearchConceptsAndrogen-independent human prostate cancer cell linesMixed estrogen agonist/antagonistProstate cancer cell linesHuman prostate cancer cell linesEstrogen agonist/antagonistAgonists/antagonistsCancer cell linesER betaER alphaCell linesDU145 cellsSelective estrogen receptor modulatorsEffects of raloxifeneEstrogen receptor modulatorsPC3M cellsDose-dependent mannerCell deathM raloxifeneWestern blot analysisTime-dependent mannerRaloxifene treatmentReceptor modulatorsBreast cancerPan-caspase inhibitor zVADRaloxifeneRaloxifene, a selective estrogen receptor modulator, induces apoptosis in androgen-responsive human prostate cancer cell line LNCaP through an androgen-independent pathway.
Kim I, Seong D, Kim B, Lee D, Remaley A, Leach F, Morton R, Kim S. Raloxifene, a selective estrogen receptor modulator, induces apoptosis in androgen-responsive human prostate cancer cell line LNCaP through an androgen-independent pathway. Cancer Research 2002, 62: 3649-53. PMID: 12097269.Peer-Reviewed Original ResearchConceptsSelective estrogen receptor modulatorsHuman prostate cancer cell line LNCaPAndrogen-independent pathwayProstate cancer cell line LNCaPCancer cell line LNCaPEstrogen receptor modulatorsCell line LNCaPLNCaP cellsER betaReceptor modulatorsAndrogen-sensitive human prostate cancer cell line LNCaPAndrogen-sensitive human prostate cancer cell line LNCaP.Mixed estrogen agonist/antagonistHuman prostate cancer cell line LNCaP.Estrogen agonist/antagonistProstate-specific antigen assaysEffects of raloxifeneProstate cancer cell line LNCaP.Androgen receptor activityPresence of antiandrogensDose-dependent mannerAgonists/antagonistsSelective ER modulatorsAndrogen response elementAntigen assaysRaloxifene, a Mixed Estrogen Agonist/Antagonist, Induces Apoptosis through Cleavage of BAD in TSU-PR1 Human Cancer Cells*
Kim H, Kim B, Kim I, Mamura M, Seong H, Jang J, Kim S. Raloxifene, a Mixed Estrogen Agonist/Antagonist, Induces Apoptosis through Cleavage of BAD in TSU-PR1 Human Cancer Cells*. Journal Of Biological Chemistry 2002, 277: 32510-32515. PMID: 12084714, DOI: 10.1074/jbc.m202852200.Peer-Reviewed Original ResearchMeSH KeywordsAmino Acid Chloromethyl KetonesAntineoplastic AgentsApoptosisBcl-Associated Death ProteinBcl-X ProteinCarrier ProteinsCaspase 3CaspasesCell DivisionCell MembraneCell NucleusCycloheximideCytochrome c GroupDNA FragmentationDose-Response Relationship, DrugEstrogen Receptor ModulatorsHumansIn Situ Nick-End LabelingMembrane PotentialsMitochondriaPhosphorylationProtein BindingProtein Synthesis InhibitorsProto-Oncogene Proteins c-bcl-2Raloxifene HydrochlorideRetroviridaeTime FactorsTumor Cells, CulturedUrinary Bladder NeoplasmsConceptsMixed estrogen agonist/antagonistTSU-Pr1 cell linesEstrogen agonist/antagonistTSU-Pr1 cellsAgonists/antagonistsCell linesSelective estrogen receptor modulatorsHuman bladder transitional cell carcinoma cell lineEffects of raloxifeneTransitional cell carcinoma cell linesProstate cancer cell linesEstrogen receptor modulatorsCell carcinoma cell linesEstrogen receptor betaHuman bladder cancerDose-dependent mannerEvidence of apoptosisCancer cell linesRaloxifene treatmentCarcinoma cell linesBladder cancerReceptor modulatorsBreast cancerHuman cancer cellsRaloxifene